Rahul Aggarwal

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?
    Rahul R Aggarwal
    Division of Hematology Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
    Urol Oncol 31:522-30. 2013
  2. pmc Castration-resistant prostate cancer: targeted therapies and individualized treatment
    Rahul Aggarwal
    Department of Medicine, University of California, San Francisco, CA 94143 1270, USA
    Oncologist 16:264-75. 2011
  3. pmc The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (
    Rahul Aggarwal
    Division of Hematology Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
    Cancer 119:3636-43. 2013
  4. doi request reprint The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels
    Rahul Aggarwal
    Urologic Oncology Program, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94115, USA
    Clin Genitourin Cancer 7:E71-6. 2009

Detail Information

Publications4

  1. doi request reprint Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?
    Rahul R Aggarwal
    Division of Hematology Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
    Urol Oncol 31:522-30. 2013
    ..Using the development of IR and/or obesity may represent a clinically available biomarker that may predict those patients most likely to respond to such therapy, and warrants testing in future prospective clinical trials...
  2. pmc Castration-resistant prostate cancer: targeted therapies and individualized treatment
    Rahul Aggarwal
    Department of Medicine, University of California, San Francisco, CA 94143 1270, USA
    Oncologist 16:264-75. 2011
    ..Additionally, lessons learned through the application of these technologies to prostate cancer may subsequently influence therapeutic development in other solid tumors...
  3. pmc The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (
    Rahul Aggarwal
    Division of Hematology Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
    Cancer 119:3636-43. 2013
    ....
  4. doi request reprint The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels
    Rahul Aggarwal
    Urologic Oncology Program, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94115, USA
    Clin Genitourin Cancer 7:E71-6. 2009
    ..This current analysis reports the relationship of change in adrenal androgen levels and prostate-specific antigen (PSA) response in patients with CRPC treated with estrogen therapy...